Endospan receives $25m from Cryolife

Endospan, an innovative Israeli-based Aortic Arch medical device company, secures a $25 million financing from CryoLife [NYSE:CRY].

Clipperton acted as sole financial advisor to Endospan.

This transaction highlights Clipperton expertise in cross-border transactions after a series of completed deals within the last 12 months – e.g. NetRange (DE) /Access Co (JP), Musement (IT) / TUI (DE), Vide Dressing (FR) /Adevinta (NO), Givve (DE) / Up Group (FR), Matooma (FR) / Wireless Logic Group (UK).


raises $25 million led by


Press release (extract)

Clipperton is pleased to announce that it acted as sole financial advisor to Endospan on its financing with purchase option to CryoLife [NYSE:CRY]. Endospan is an Israeli-based, privately-held developer of NEXUS™, the first approved branched endovascular system to treat aortic arch disease, transforming a complex surgical aortic arch repair into a standard endovascular procedure. The addition of NEXUS to CryoLife’s highly differentiated branched aortic stent graft portfolio further strengthens the Company’s position as a leader in the growing aortic repair market. READ FULL PR

Go back